This newsletter presents you the following key sessions:
1. Olaparib plus abiraterone as first-line therapy for patients with metastatic castration-resistant prostate
cancer
2. Continued survival and quality of life benefit of cabozantinib-nivolumab over sunitinib as first-line
treatment of advanced clear-cell renal cell carcinoma
3. Adding darolutamide to docetaxel and androgen deprivation therapy significantly prolongs the
survival of patients with metastatic hormone sensitive prostate cancer
4. Atezolizumab fails to meet PFS endpoint in advanced squamous cell carcinoma of the penis
5. Lenvatinib fails to improve on pembrolizumab in patients with advanced urothelial carcinoma